Update on the Safety of Biologic Agents in the Treatment of Psoriasis

Update on the Efficacy of Biologic Agents in Psoriasis

Differences in the Clinical Profiles of the Biologic Agents May Be Due to Differences in Mechanism of Action

Summary

References
Ongoing Developments in Biologic Therapy




Registration benefits include:
Access to CME/CE programs and certification
Free subscription to Biologic Bulletin newsletter
Reminders of new CME/CE activities
REGISTER NOW

This Web site is supported by an
unrestricted educational grant from
Genentech, Inc.
Meetings/Links : Meeting Reports : Psoriasis and Biologic Therapy
References

  1. Gordon KB. Safety of biologics. In: Feldman SR. Psoriasis. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. SYM 302.


  2. Lebwohl M. Advances in the treatment of psoriasis. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. PLN 152.


  3. Wolverton SE. Is there a risk of lymphoma from biologic therapy for psoriasis? In: Wolverton SE. Therapies and how medications work. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. SYM 313.


  4. Goffe B, Papp K, Gratton D, et al. Long-Term safety of alefacept in patients who have received up to nine courses of therapy. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 2773.


  5. Tyring S, Rosoph L, Toth D, et al. A 2-year phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis: results from the 3-month double-blind period. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 2700.


  6. Lebwohl MG, Gottlieb AB, Wallis WJ, et al. Safety and efficacy of over 7 years of etanercept therapy in a global population of patients with rheumatoid arthritis. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 2792.


  7. Gottlieb AB, Gordon KB, Hamilton TK, et al. Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: final phase IIIb study results. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 4.


  8. Menter A, Hamilton TK, Caro I, et al. Safety and tolerability of efalizumab therapy for patients with moderate to severe chronic plaque psoriasis: results of an open-label phase IIIb multicenter trial. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 2793.


  9. Gottlieb AB, Grekin S, Maloney JM, et al. Preliminary results of EDUCATE, a multicenter, community-based, open-label study of the effect on skin and joint disease in patients with psoriatic arthritis. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 2780.


  10. Antoni C, Kavanaugh A, Guzzo C, et al. IMPACT and IMPACT 2: consistent skin response to infliximab across studies in patients with psoriatic arthritis. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 2764.


  11. Langley R, Leonardi C, Toth D, et al. Long-Term safety and efficacy of adalimumab in the treatment of moderate to severe chronic plaque psoriasis. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 6.


  12. Blum R, Lebwohl M, Wong V, et al. Durability of treatment response in patients with moderate to severe psoriasis following withdrawal from or a dose reduction in adalimumab therapy. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 2737.


  13. Menter M, Gordon K, Leonardi C, et al. Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 2713.


  14. Menter A, Cather JC, Baker D, et al. Long-Term use of alefacept: efficacy in patients who have received multiple course of therapy. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 7-PDS.


  15. Papp KA, Langley RGB, Shear NH, et al. Efficacy and safety of efalizumab therapy in high-need psoriasis patients. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 2746.


  16. Kohno T, Stevens SR, Louie JS. Adalimumab and infliximab bind to Fc-receptor and C1q and generate immunoprecipitation–a different mechanism from etanercept. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 400.


  17. Lizzui P, Aphale A, Malaviya R, et al. Differential expression of active phosphorylated NF-kB by etanercept. Presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. Poster 2827.


Previous